Fig. 3From: The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trialChanges in oxidative stress markers at week 26 from baseline. A significant increase observed in SOD enzyme activity, GSHr, and TAC in empagliflozin group compared to placebo, while a significant reduction observed in lymphocytic ROS (P < 0.05). SOD: Superoxidase dismutase, CAT Catalase enzyme activity, GSH Reduced Glutathione, ROS Reactive oxygen species, TAC Total antioxidant capacity, MDA MalondialdehydeBack to article page